Clinical trial
A Phase I Study of Safety, Tolerability and Pharmacokinetics of T-1301 Capsules in Subjects With Advanced Solid Tumors
NCT05156203 is registered in ClinicalTrials.gov with Taivex Therapeutics Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study of Safety, Tolerability and Pharmacokinetics of T-1301 Capsules in Subjects With Advanced Solid Tumors
- Lead sponsor
- Taivex Therapeutics Corporation
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- December 19, 2021
- Completion date
- December 31, 2027
- Enrollment
- 30 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
advanced solid tumor, lymphoma